Heparin-induced thrombocytopenia in children: 12 new cases and review of the literature

Summary

Immune-mediated heparin-induced thrombocytopenia (HIT) is a rare but severe adverse effect of heparin therapy. Only few data are available on clinical presentation, diagnosis and management of HIT in children. Records of all patients sent to our laboratory between 1995 and November 2003 were reviewed. To identify literature reports a Medline search was performed, the reference lists of those publications were screened and the abstracts of meetings on thrombosis and hemostasis between 2000 and 2003 were assessed. We identified 12 new HIT patients between 13 months and 18 years of age from our laboratory and 71 reports on HIT in children in the literature. For the assessment of frequency of HIT all studies enrolling > 100 patients were analyzed. HIT is rare in children. In pediatric patients, there seem to be two risk groups: newborns and infants under 4 years of age undergoing cardiac surgery (incidence ∼ 1-2%), and teenagers treated with heparin for thrombosis. For confirmation of HIT in children, antigen assays are most important. There are conflicting data on the optimal cut-off, with one randomized, double-blind trial indicating that the cut-off established in adults is appropriate.

There are no systematic studies on alternative anticoagulants in children affected by HIT. Most data are available for lepirudin and danaparoid. Substitution of unfractionated heparin by low-molecular-weight heparins for regular anticoagulation may reduce the incidence of HIT.

Keywords

Heparin-induced thrombocytopenia - children - cardiac surgery - lepirudin - danaparoid

• References

• 1 Warkentin TE. Clinical picture of heparininduced thrombocytopenia. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia. 3rdEd.. New York, NY: Marcel Dekker; 2003: 53-106.
• 2 Ranze O, Rakow A, Ranze P. et al.. Low-dose danaparoid sodium catheter flushes in an intensive care infant suffering from heparininduced thrombocytopenia. Pediatr Crit Care Med 2001; 02: 175-7.
• 3 Sauer M, Gruhn B, Fuchs D. et al.. [Heparininduced type II thrombocytopenia within the scope of high dose chemotherapy with subsequent stem cell rescue]. Klin Padiatr 1998; 210: 102-5.
• 4 Suh JS, Aster RH, Visentin GP. Antibodies from patients with heparin-induced thrombo-cytopenia/thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 1998; 91: 916-22.
• 5 Zöhrer B, Zenz W, Rettenbacher A. et al.. Danaparoid sodium (Orgaran) in four children with heparin-induced thrombocytopenia type II. Acta Paediatr 2001; 90: 765-71.
• 6 Schiffmann H, Unterhalt M, Harms K. et al.. [Successful treatment of heparin-induced thrombocytopenia type II in childhood with recombinant hirudin]. Monatsschr Kinderheilkd 1997; 145: 606-12.
• 7 Boshkov LK, Ibsen L, Kirby A. et al.. Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases. J Thromb Haemost 2003; 1 (Suppl. 01) P1494.
• 8 Nguyen TN, Gal P, Ransom JL. et al.. Lepirudin use in a neonate with heparininduced thrombocytopenia. Ann Pharmacother 2003; 37: 229-33.
• 9 Schmugge M, Risch L, Huber AR. et al.. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109: E10.
• 10 Girisch M, Klinge J, Lischetzki G. et al.. In neonates higher doses orgaran may be needed to achieve effective doses. Ann Hematol 2002; 81 (Suppl. 01) A22.
• 11 Butler TJ, Sodoma LJ, Doski JJ. et al.. Heparin-associated thrombocytopenia and thrombosis as the cause of a fatal thrombus on extracorporeal membrane oxygenation. J Pediatr Surg 1997; 32: 768-71.
• 12 Murdoch IA, Beattie RM, Silver DM. Heparin-induced thrombocytopenia in children. Acta Paediatr 1993; 82: 495-7.
• 13 Ranze O, Ranze P, Magnani HN. et al.. Heparin-induced thrombocytopenia in paediatric patients – a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr 1999; 158 (Suppl. 03) S130-S133.
• 14 Oriot D, Wolf M, Wood C. et al.. [Severe thrombocytopenia induced by heparin in an infant with acute myocarditis]. Arch Fr Pediatr 1990; 47: 357-9.
• 15 Newall F, Barnes C, Ignjatovic V. et al.. Heparin-induced thrombocytopenia in children. J Paediatr Child Health 2003; 39: 289-92.
• 16 Saxon BR, Black MD, Edgell D. et al.. Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran). Ann Thorac Surg 1999; 68: 1076-8.
• 17 Severin T, Dittrich S, Zieger B. et al.. HIT II after Fontan procedure – treatment with Lepirudin. Ann Hematol 2002; 81 (Suppl. 01) A77.
• 18 Porcelli R, Moskowitz BC, Cetta F. et al.. Heparin-induced thrombocytopenia with associated thrombosis in children after the Fontan operation: report of two cases. Tex Heart Inst J 2003; 30: 58-61.
• 19 Deitcher SR, Topoulos AP, Bartholomew JR. et al.. Lepirudin anticoagulation for heparininduced thrombocytopenia. J Pediatr 2002; 140: 264-6.
• 20 Severin T, Zieger B, Sutor AH. Anticoagulation with recombinant hirudin and danaparoid sodium in pediatric patients. Semin Thromb Hemost 2002; 28: 447-54.
• 21 Bocquet R, Blanot S, Dautzenberg MD. et al.. [Antiphospholipid antibody syndrome in pediatric neurosurgery: a hemostasis problem]. Ann Fr Anesth Reanim 1999; 18: 991-5.
• 22 Potter C, Gill JC, Scott JP. et al.. Heparininduced thrombocytopenia in a child. J Pediatr 1992; 121: 135-8.
• 23 Wilhelm MJ, Schmid C, Kececioglu D. et al.. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg 1996; 61: 920-4.
• 24 Klement D, Rammos S, Kries R. et al.. Heparin as a cause of thrombus progression. Heparin-associated thrombocytopenia is an important differential diagnosis in paediatric patients even with normal platelet counts. Eur J Pediatr 1996; 155: 11-4.
• 25 Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001; 27: 293-9.
• 26 Klenner AF, Fusch C, Varnholt V. et al.. [Heparin-induced thrombocytopenia in pediatrics and its therapy-case-report and review of literature]. Monatsschr Kinderheilkd 2003; 151: 1180-7.
• 27 Weigel B, Laky A, Krishnamurti L. Danaparoid (Orgaran) anticoagulation of pediatric patients with heparin-induced thrombocytopenia (HIT). J Pediatr Hematol Oncol 1999; 21: 327.
• 28 Neuhaus TJ, Goetschel P, Schmugge M. et al.. Heparin-induced thrombocytopenia type II on hemodialysis: switch to danaparoid. Pediatr Nephrol 2000; 14: 713-6.
• 29 Boon DM, Michiels JJ, Stibbe J. et al.. Heparin-induced thrombocytopenia and antithrombotic therapy. Lancet 1994; 344: 1296.
• 30 Spadone D, Clark F, James E. et al.. Heparininduced thrombocytopenia in the newborn. J Vasc Surg 1992; 15: 306-11.
• 31 Girisch M, Buheitel G, Ries M. et al.. Safe and effective use of Danaparoid during cardiac catheterization in a 14 month old boy with tetralogy of Fallot and heparin-induced thrombocytopenia. Ann Hematol 2001; 80 (Suppl. 01) A68.
• 32 Klenner AF, Fusch C, Rakow A. et al.. Benefit and risk of heparin for maintaining peripheral venous catheters in neonates: A placebo-controlled trial. J Ped 2003; 143: 741-5.
• 33 Risch L, Fischer JE, Schmugge M. et al.. Association of anti-heparin platelet factor 4 antibody levels and thrombosis in pediatric intensive care patients without thrombocytopenia. Blood Coagul Fibrinolysis 2003; 14: 113-6.
• 34 Warkentin TE, Levine MN, Hirsh J. et al.. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-5.
• 35 Pouplard C, May MA, Iochmann S. et al.. Antibodies to platelet factor 4-heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin : clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99: 2530-6.
• 36 Albisetti M, Andrew M. Low molecular weight heparin in children. Eur J Pediatr 2002; 161: 71-7.
• 37 Massicotte P, Julian JA, Gent M. et al.. An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial. Thromb Res 2003; 109: 101-8.
• 38 Massicotte P, Julian JA, Gent M. et al.. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003; 109: 85-9.